Meiji Seika Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C12375)
◆英語タイトル:Meiji Seika Pharma Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12375
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年12月
◆ページ数:42
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Meiji Seika Pharma Co Ltd (Meiji Seika Pharma), a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider that carries out manufacturing and sale of ethical pharmaceuticals, agricultural chemicals and veterinary drugs. The company provides Streptomycin Meiji, Kanamycin Meiji, Habekacin, Orapenem, Reflex, Sycrest , Depromel and others. It own and operates manufacturing and development technologies which provides a series of excellent antibacterial drugs. Meiji Seika Pharma also carries out research and development programs on infectious diseases and central nervous system disorders. The company offers its products for human and veterinary care. It operates research center, laboratories, and agricultural and veterinary research laboratories in Japan. Meiji Seika Pharma is headquartered in Tokyo, Japan.

Meiji Seika Pharma Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
Advent International Rumored To Acquire 25% Stake In Medreich From Temasek 13
Partnerships 14
Meiji Seika Pharma Enters into Agreement with Santen Pharma 14
Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 15
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 16
Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 17
Meiji Seika Pharma Enters into Agreement with Ohki Pharma 18
AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 19
Licensing Agreements 20
Meiji Seika Pharma Receives Rights of Epadail S from Mochida Pharma 20
Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 21
Eisai Enters into Licensing Agreement with Meiji Seika Pharma 22
Meiji Seika Pharma Enters into Licensing Agreement with Solasia Pharma for Episil 23
Solasia Pharma Enters into Licensing Agreement with Meiji Seika Pharma for Darinaparsin 24
Meiji Seika Pharma Enters into Licensing Agreement with MSD 25
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 26
Curadim Pharma Enters into Licensing Agreement with Meiji Seika Pharma 28
Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 29
Acquisition 30
Meiji Acquires 49% Stake in Kaketsuken for USD0.16 Billion 30
Meiji Seika Pharma Acquires Medreich Lifecare for USD290 Million 32
Meiji Seika Pharma Co Ltd – Key Competitors 33
Meiji Seika Pharma Co Ltd – Key Employees 34
Meiji Seika Pharma Co Ltd – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Joint Venture 36
Recent Developments 37
Corporate Communications 37
Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia 37
Product News 38
04/12/2018: Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology 38
Clinical Trials 39
Jun 05, 2018: Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018 39
Oct 20, 2017: Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Meiji Seika Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advent International Rumored To Acquire 25% Stake In Medreich From Temasek 13
Meiji Seika Pharma Enters into Agreement with Santen Pharma 14
Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 15
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 16
Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 17
Meiji Seika Pharma Enters into Agreement with Ohki Pharma 18
AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 19
Meiji Seika Pharma Receives Rights of Epadail S from Mochida Pharma 20
Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 21
Eisai Enters into Licensing Agreement with Meiji Seika Pharma 22
Meiji Seika Pharma Enters into Licensing Agreement with Solasia Pharma for Episil 23
Solasia Pharma Enters into Licensing Agreement with Meiji Seika Pharma for Darinaparsin 24
Meiji Seika Pharma Enters into Licensing Agreement with MSD 25
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 26
Curadim Pharma Enters into Licensing Agreement with Meiji Seika Pharma 28
Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 29
Meiji Acquires 49% Stake in Kaketsuken for USD0.16 Billion 30
Meiji Seika Pharma Acquires Medreich Lifecare for USD290 Million 32
Meiji Seika Pharma Co Ltd, Key Competitors 33
Meiji Seika Pharma Co Ltd, Key Employees 34
Meiji Seika Pharma Co Ltd, Other Locations 35
Meiji Seika Pharma Co Ltd, Subsidiaries 35
Meiji Seika Pharma Co Ltd, Joint Venture 36

List of Figures
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Meiji Seika Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報(Meiji Seika Pharma Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆